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Introduction
The discovery of antibiotics in the middle of the 20 th century significantly decreased the morbidity and mortality associated with infectious diseases. However, the ability of microorganisms to develop resistance to antimicrobial agents has been of concern since the first report of reduced susceptibility to penicillin of Streptococcus pneumoniae in 1965 1 . This has now become a major public health issue, noted by the Chief Medical Officer for England in her 2013 annual report 2 and the subject of a World Health Assembly meeting which developed a global plan of action 3 .
Since many of the first antibiotics were naturally occurring substances, researchers have continued to investigate anecdotal evidence and folklore to find new antimicrobial agents. This has led to the discovery that, for example, a topical preparation of the esse tial oil tea tree (Melaleuca alternifolia) from Australia has antiseptic and anti-inflammatory properties 4 , and that the Chinese herbal remedy qinghaosun (artemisinin) derived from Artemisia annua is an effective anti-malarial 5 .
Copper, which was advocated by Hippocrates for the treatment of leg ulcers, is microbicidal and therefore has a useful role in infection control when incorporated into frequently touched surfaces in hospitals 6 .
One area of current interest is antimicrobial peptides (AMPs) in invertebrates. These are relatively small ( 5-15 kDa ) molecules which are part of the animal s natural defence system 7 Examples which have been characterised from molluscs include defensins, mytilins, myticins and mytimacins 8, 9 .
Most of the AMPs described to date are found in the haemolymph of the invertebrate and the literature suggests they have activity against an eclectic mix of microorganisms including bacteria, viruses and protozoa 8 .
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A range of internal AMPs have been found in gastropods, but it is also likely that their external secretions would have components affording protection against potential pathogens, in a similar manner to the antimicrobial substances found in the mucous of fish and amphibians 10, 11. .
Terrestrial slugs and snails produce mucous which performs a variety of functions, including facilitating movement along the ground, communication and a non-specific, defensive response to physical or chemical irritation 12 .
The antimicrobial properties of the mucous collected from African giant land snails ( Achatina fulica)
were first described in the 1980s, by researchers in Japan 13, 14 . These authors reported finding that when mucous was mixed with water and centrifuged, the resulting supernatant exhibited antimicrobial activity in a standard disc diffusion assay 13 . Biochemical investigations of the nature of the active ingredient led to the conclusion that it is a glycoprotein 13 of around 140 -160,000 Da 14, 15 , which they subsequently named Achaci
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. 17 formulated mucous into a wound dressing preparation, which was applied to skin lesions on the backs of rats. They presented histological results suggesting that the A.fulica mucous promoted wound healing 17 , but specific antimicrobial activity in vivo was not reported.
The brown garden snail, Helix aspersa has been used in human medicine since antiquity: Hippocrates recommended snail mucus for the treatment of protocoele whilst Pliny stated that snail preparations could be employed in everything from childbirth to nosebleeds 18 . Recently, anecdotal reports of generic skin regeneration properties of the mucous from H. aspersa have been explored 19 ; this has resulted in the commercial production of a topical preparation 20 which is claimed to have wou d heali g as well as a ti-ageing properties. Tsoutsos et al. 19 tested the preparation on burns patients and while they noted that a range of opportunistically pathogenic bacteria were isolated from swabs collected from the wounds before treatment, this was not followed up with culture of post treatment specimens. Thus, the specific antimicrobial properties of H.aspersa mucous do not appear to have been researched.
Therefore the aim of this study was to investigate the antimicrobial properties of mucous from the common garden snail Helix aspersa and to characterise any active ingredient(s) discovered. Since most of the previously published work in this area related to Achatina fulica, analysis of mucous from this species of mollusc was also included for comparison.
Method

Snail care and mucous collection Helix aspersa
Twenty snails were collected from the wild and kept indoors in a clear plastic tank (35 x 22 x 14cm)
at room temperature (~21 0 C) and ambient light. They were fed on lettuce leaves, cucumber, carrots and apples and provided with water, along with a source of calcium. The tanks were cleaned weekly.
Mucous production was encouraged by taking each individual snail and gently stimulating it with a cotton swab moistened in phosphate buffered saline (PBS). The resulting secretions were collected using 10ml plastic Pasteur pipettes and pooled into one aliquot. The mucous was left to settle at room temperature for 1-2hours before dilution at 1:3 in PBS and centrifugation at 4500rpm for 20 minutes. The supernatant was used in subsequent investigations.
Achatina fulica
Four captive bred juvenile snails were made available for this study courtesy of Dr Sally Willliamson, Liverpool John Moores University. They were maintained under the same conditions as the H.aspersa snails, except that the tank was slightly deeper (35 x 22 x 21cm) and their diet was cucumber and butternut squash. Mucous production and collection was carried out in a similar manner to that described above for the garden snails. The mucous was diluted in PBS and processed to obtain supernatant as described above. (Oxoid, Basingstoke, Hampshire, UK) was used to test the activity against C.albicans. Three sterile paper assay discs ( 5 mm diameter) were applied to each plate and 50L of the mucous supernatant was added to two of them, while the third was treated with 50L PBS as a control. Plates were incubated at 37 0 C for 18-24 hours before being read. Zones of inhibition were recorded in mm. For most of the organisms tested the assay was performed twice and a mean zone of inhibition was calculated. For the two strains of P.aeruginosa, the assay was performed four times, generating eight readings from which the mean was taken.
Initial antimicrobial assay
After analysis of the results from the initial antimicrobial assay, the effect of H. aspersa mucous on
Pseudmonas aeruginosa was investigated in more detail and a third strain, namely Pseudomonas aeruginosa NCTC 10662 was included. At this point, the A. fulica mucous was introduced into the 7 study for comparison and both types of mucous were also tested against Escherichia coli NCTC 10385, Staphylococcus aureus NCTC 10788 and Candida albicans ATCC 10231.
Biochemical analysis
An aliquot of 1:3 diluted H.aspersa mucous supernatant was analysed for protein content using the Biuret method. The result was obtained in g/L which was then calculated as mg/mL for the undiluted mucous.
Size separation assays
Approximately 500L aliquots of the mucous supernatant were processed in a series of Vivaspin 500
protein size separator columns (Sartorious, Epsom, Surrey, UK) at 1,000 kDa, 100 KDa, 30 kDa and 10
KDa followi g the a ufacturer s i structio s -including pre-rinsing in distilled water to remove sodium azide. The results of testing the supernatant of the H.aspersa mucous after 1:3 dilution in PBS against a range of organisms are shown in Table 1 . Clear, measurable zones of inhibition were obtained with 9 the two P.aeruginosa strains (Table 1 , Figure 1 ), but no effect was observed for any of the other microorganisms. Tables 2a and 2b indicate the outcomes from protein size separation experiments. They show that the antimicrobial activity was found in the filtrate from the 1, 000 kDa column for both types of mucous and against the two organisms where zones of inhibition were observed. For the H.aspersa mucous, these results located the protein(s) of interest at between 30 and 100 kDa in size (Table 2a) , while the active ingredient in A.fulica mucous appeared to be around 100 kDa (Table 2b) No bacteriophage activity was found in the H.aspersa or A.fulica mucous against the target organisms tested in either the direct or enrichment assay (Table 3) . Although there was some faint clearing observed in the direct assay with Serratia marcescens, on further investigative sampling, no active bacteriophage were isolated.
Discussion
This study has shown that the mucous from the common brown garden snail, Helix aspersa, has a demonstrable antimicrobial activity against several strains of Pseudomonas aeruginosa. The bacteriophage assay results indicated that this is not an effect caused by bacteriophage in the mucous. Previous studies on the antimicrobial activity of snail mucous have not tested for this, although bacteriophages have recently been shown to adhere to the mucous from a wide of organisms, including humans, thus contributing to the antimicrobial response 22 .
While the concentration of the active ingredient(s) was not ascertained, clear and repeatable zones of inhibition were observed when the mucous was diluted in PBS but not subject to any other preparation ( Figure 1 ). The diameter of the assay disc was 5mm, which meant that the specific antimicrobial effect accounted for over 6mm in the recorded zones (Table 1 ). This effect against P.aeruginosa was initially found in the unseparated mucous supernatant and subsequent investigations indicated the active ingredient to be between 30 and 100 kDa. As Table 2a shows, antimicrobial effect was found in the concentrate after the 30 kDa size separation and the filtrate after the 100kDa step. Electrophoresis results confirmed that two proteins were present in H.aspersa mucous in this size region -one between 50 and 60 kDa and one approximately 35kDa in size ( Figure 4 ). Resistance by P.aeruginosa to currently available antimicrobials is an increasing problem in clinical practice 23 . Therefore this is a significant result, which does not appear to have been reported previously.
In contrast, A.fulica mucous was not found to have activity against any of the strains of P.aeruginosa included in this study, either in the unseparated form or after any of the size separation processes.
This was unexpected, since it contradicts previously reported studies 13, 14 , which apparently showed a strong effect against this bacterium. It is not clear why this should be the case, but the present 11 findings appear to concur with those of Santana et al. 17 , who did not report any results from their tests using P.aeruginosa ATCC 1024.
During the study, it was discovered that the use of the 1, 000 kDa column was a useful concentration step; the active ingredient(s) were retained and it enhanced the effect of both types of mucous against S.aureus. (Tables 2a and 2b ; Figures 3a and 3b) . By using this processing prior to the antimicrobial assays, it was found that H. aspersa mucous also had an inhibitory effect against
Staphylococcus aureus, although it was less marked (Figure 3a) . A similar effect was noted with the A.fulica mucous (Table 2b , Figure 3b) . The fact that A.fulica mucous was found to be active against S.
aureus does concur with previous work 13, 14, 15, 16, 17 , although none of the other authors report the relatively weak effect found in the present study. However, apart from Santana et al. 17 , all describe isolating the active ingredient -i.e. Achacin 13, 14, 15 or Mytimycin-AF 16 -before testing it against the bacteria. Santana et al. 17 , seem to have followed a very similar antimicrobial assay method to that employed in the present study, with the exception of their use of Mueller -Hinton agar instead of ISA and wells in the agar instead of discs. They reported that an aliquot of 5L of A.fulica mucous did not inhibit growth of S. aureus, but that an effect was noted at 10L and 20L
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. They did not attempt to separate out the protein content or concentrate the mucous in any way, so this supports the idea that the effect is enhanced when more of the active ingredient is available to interact with the bacterium.
The H.aspersa mucous was not found to be effective against a range of other bacteria or Candida albicans . Initially this finding was rather unexpected, since components of A.fulica mucous have previously been reported to inhibit the growth of E.coli 15, 16 , a number of Bacillus species 13, 16 and K.pneumoniae 16 as well as C.albicans 16 . Extrapolating from the literature it seemed possible that H.aspersa mucous might have a similar broad spectrum of activity, which is why a variety of organisms were tested in the initial antimicrobial assay. However, this study was not able to reproduce the antimicrobial effect of A.fulica mucous against E.coli, C.albicans or P.aeruginosa. It is possible that this discrepancy is due to variations in methodology or the strains of organisms used.
However, Santana et al. 17 also tested A.fulica mucous using a simple method (involving whole mucous rather than particular fractions) against a range of organisms and similarly reported an effect for Staphylococcus species only. They used different type culture collection organisms for E.coli, P.aeruginosa and indeed S. aureus to the present study 17 , which shows that strain variation is unlikely to be the explanation. By coincidence, they used the same C.albicans (ATCC 10231) and found the same (negative) result. In this study, size separation was used to isolate and concentrate the active ingredient (see below), but no effect was observed when A.fulica mucous was tested against E.coli, P. aeruginosa or C.albicans (Table 2b ). This all suggests that the finding of a limited activity for H.aspersa mucous is likely to be genuine.
The H.aspersa mucous contained 4.8 mg/mL protein, which is comparable to the 4mg/mL reported by Iguchi et al. 13 in A.fulica mucous. The size separation experiments (Table 2a) indicated that there were no proteins of less than 30 kDa active against the microorganisms under test in this study. This size and specificity means that it is unlikely that the antimicrobial activity is associated with lysozymes, which are known to be present in snails and their mucous 24 . Invertebrate lysozymes are usually small proteins with molecular weight of around 15kDa. It also indicates that an antimicrobial compound analogous to Mytimacin-AF 16 or any other AMP 8 is unlikely to be present. In this study, the substance which was active against S.aureus in A.fulica was present in both the filtrate and the concentrate after separation in the 100 kDa column. This was a surprise, since Achacin is reported to be a protein of 160 kDa, formed of two subunits of 70-80 kDa each 14 . It would be expected that only the whole molecule would be active in the antimicrobial assays and that the effect would therefore have been seen solely in the 100kDa concentrate, but it was not (Table 2b ).
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Size separation experiments indicated that the antimicrobial effect in the H.aspersa mucous was due to one or more proteins of between 30 and 100kDa in size (Table 2a) kDa and between 50 and 60 kDa (Figure 4 ), but they were comparatively faint, suggesting that these proteins were present in relatively low concentrations. It therefore could be that H.aspersa mucous does indeed contain an antimicrobial protein which corresponds to Achacin and is of a similar size, but that it is was not detectable by the biochemical methods used in this study. This idea is supported by the fact that mucous from both species of snail produced a similar, albeit relatively weak, antimicrobial effect against S. aureus in the assay used here (Figures 3 a and 3 b) and Achacin is reported to be effective in killing this Gram positive coccus 15 . However the ingredient active against S.aureus in the H.aspersa mucous was clearly within the 30-100 kDa range and it is possible that one of the two proteins identified in this region are responsible for the anti-staphylococcal effect.
The activity of the H.aspersa mucous against P.aeruginosa appears to be stronger and there are two possible explanations for this. One is that there is an Achacin-like protein and that it interacts differently with the P.aeruginosa. This is plausible since Otsuka-Fuchin et al. 15 suggested that
Achacin could be targeting cell wall synthesis and P.aeruginosa is a Gram negative bacillus, with a different cell wall composition to S.aureus. Alternatively, since antimicrobial agents exploit peculiarities in prokaryotic metabolism, this protein could be interfering with a species specific pathway. The other possibility is that one or both of the two smaller proteins (30-40 kDa and 50-60kDa in size) identified as potential antimicrobials in H.aspersa mucous are affecting the P.aeruginosa. The strength of the effect on bacteria of this species (Figures 1a, 1b and 2) could be because the two substances interact to achieve the anti-microbial effect. Further work to fully characterise the active ingredient(s) and exploration of the specific antimicrobial effects should clarify this
Although the results presented here were repeatable, it was not possible to confirm many of the previously published findings with A. fulica. This could be due to the low concentration of the active ingredient(s) in the mucous as it was collected and processed in this study. It is therefore possible that H.aspersa has a broader spectrum of activity than found here, analogous to that reported by other authors for A.fulica. Once the active ingredient has been fully characterised, tests with the wide range of microorganisms used in initial antimicrobial assay in this study could be repeated.
Further work would include obtaining a profile of the protein content for example using matrix assisted laser desorption/ionisation (MALDI) and then isolating fractions of the mucous protein without denaturing them -using for example high performance liquid chromatography (HPLC) or native gel electrophoresis; the individual fractions could then be put into the antimicrobial assay in order to determine the exact size of the active ingredient(s). Once this was known, the protein could be sequenced and fully characterised which would allow elucidation of its site and mode of action against relevant microorganisms.
In this study, H.aspersa mucous was found to be equally effective against three laboratory strains of P.aeruginosa. The next phase therefore would be to test it (in vitro) against clinical isolates. If this proves successful, then the effectiveness of the topical preparation, such as the one already available commercially 19 could be explored.
The antimicrobial activity in H.aspersa mucous appears to be caused by one or more novel substances with molecular weight between 30 and 100 kDa. There is a particularly strong inhibitory effect against P.aeruginosa and further investigation is warranted. In all cases, PBS control discs gave a zone size of 0mm. 
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